Liquidia Technologies Inc.’s (LQDA) product candidate LIQ861, which is at the FDA altar, awaits the decision on Nov.7, 2021.LIQ861, a dry powder inhalation of treprostinil, is proposed for the treatment of pulmonary arterial hypertension (PAH).Liquidia is seeking approval for LIQ861 under the 505(b)(2) regulatory pathway and United Therapeutics Corp.’s (UTHR) Tyvaso, a nebulized treprostinil solution, is the Reference Listed Drug for the LIQ861 NDA.This is LIQ861’s second go-around with the FDA.In November 2020, the FDA declined to approve LIQ861 and sought additional information and clarification from the company on chemistry, manufacturing and controls (CMC) data pertaining to the drug product and device biocompatibility.After addressing the concerns raised by the FDA, the company resubmitted the New Drug Application for LIQ861 to the FDA in May of this year, which was accepted for review the following month.Liquidia and United Therapeutics are locked in a patent dispute over Tyvaso. In a patent suit filed last June. United Therapeutics had alleged that Liquidia Infringed on two patents for Tyvaso, which are set to expire in December 2028.LQDA closed Thursday’s trading at $3.77, up 5.31%.